



Annual Report 28th 2007 - 2008




my trusted partner IN DIAGNOSIS



*Creating products
Setting standards*


HBsAg

ICT
ELISA



HIV

SPIA
ELISA
Flow Through




MALARIA

ICT



HCV

Flow Through
ELISA




SYPHILIS

Flocculation
Flow Through



CLINICAL CHEMISTRY REAGENTS

Liquid Stable
Dry Powder
Manual Biochemistry



TUBERCULOSIS

PPD
SPIA
ELISA




TYPHOID

Agglutination



RHEUMATOLOGY

Agglutination



FILARIASIS

Flow Through




LEISHMANIASIS

Flow Through



MICROBIOLOGY

Pre-poured media
Sensitivity Discs



BGT - ANTI-SERA

Agglutination



CHOLERA

ICT



OTHER REAGENTS

1. Thromboplastin
2. Stains
3. Histology & Cytology Products
4. Ready-made Reagents
5. Photometer Scan Kit
6. Control (Haematology & Biochemistry)
7. Laboratory Instruments

BOARD OF DIRECTORS

Dr. Ramnik H. Parekh	Chairman
Smt. Lata P. Desai	Director
Dr. Pranav S. Desai	Director
Shri Praful R. Gandhi (upto 24 Aug 07)	Director
Shri Shyamal Ghosh	Director
Shri Sarvajna G. Kazi	Director
Shri Sanjay N. Mehta	Director
Dr. Sushil K. Shah	Director
Shri S. Sundaresan	Director
Shri Kamlesh Patel	Additional Director
Dr. Pradip K. Desai	Whole-time Director
Shri Veeral P. Desai	Managing Director
Dr. Madhukanta T. Patel	Technical Director

BANKERS

Kotak Mahindra Bank Ltd.
K.G. Point, Ghod Dod Road
Nr. Ganga Palace
Surat

AUDITORS

M/s. Y. B. Desai & Associates
Chartered Accountants
Surat

**HEAD OFFICE &
REGISTERED OFFICE**

173-B, New Industrial Estate
Road No.6-G, Udyognagar
Udhna, Surat 394210, India

CONTENTS**PAGE NO.**

<i>Notice of Annual General Meeting</i>	2
<i>Directors' Report</i>	4
<i>Report on Corporate Governance</i>	9
<i>Auditors' Report</i>	15
<i>Balance Sheet</i>	18
<i>Profit & Loss Account</i>	19
<i>Schedules forming part of Balance Sheet & Profit & Loss Account</i>	20
<i>Cash-flow Statement</i>	38
<i>Auditors' Report on consolidated Accounts</i>	41
<i>Consolidated Balance Sheet</i>	42
<i>Consolidated Profit & Loss Account</i>	43
<i>Schedules forming part of consolidated Balance Sheet & Profit & Loss Account</i>	44
<i>Consolidated Cash-flow Statement</i>	56



NOTICE

To THE MEMBERS OF SPAN DIAGNOSTICS LIMITED

Notice is hereby given that the 28th Annual General Meeting of Shareholders of Span Diagnostics Limited will be held at Registered Office at Plot No 173-B, New Industrial Estate, Road No.6-G, Udhna, Surat 394 210 on Saturday, the 23rd day of August, 2008 at 11.00 a.m. to transact the following business:-

ORDINARY BUSINESS

1. To receive, consider and adopt the audited Balance Sheet as at 31st March, 2008, the Profit and Loss Account for the year ended on that date and the Reports of the Directors and Auditors thereon.
2. To declare a dividend.
3. To appoint a director in place of Smt. Lataben P. Desai who retires by rotation and being eligible, offers herself for reappointment.
4. To appoint a director in place of Mr. Sanjay Mehta who retires by rotation and being eligible, offers himself for reappointment.
5. To appoint a director in place of Mr. Sarvajna Kazi who retires by rotation and being eligible, offers himself for reappointment.
6. To appoint Auditors to hold office from the conclusion of this Annual General Meeting till the conclusion of the next Annual General Meeting and to fix their remuneration. The retiring Auditors M/s. Y. B. Desai and Associates, Chartered Accountants are eligible for reappointment.

SPECIAL BUSINESS

7. To consider and, if thought fit to pass with or without modification, the following Resolution as an Ordinary Resolution.
"RESOLVED THAT Mr. Kamlesh Patel who was appointed as an additional director and holds office upto the date of this Annual General Meeting and in respect of whom the company has received a notice in writing from a member under the provisions of section 257 of the Companies Act, 1956 proposing his candidature for the office of a Director, be and is hereby appointed as a Director liable to retire by rotation."

By Order of the Board

Registered Office: 173-B, New Industrial Estate
Road No.6-G, Udhna, Surat 394 210

Dated: 28th June 2008

Jagdish Mehta
VP(Finance) & Company Secretary

NOTES:

- (a) A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT ONE OR MORE PROXIES TO ATTEND AND VOTE INSTEAD OF HIMSELF AND SUCH PROXY NEED NOT BE A MEMBER OF THE COMPANY. THE PROXY DULY COMPLETED MUST BE RETURNED TO REACH THE REGISTERED OFFICE OF THE COMPANY NOT LESS THAN 48 HOURS BEFORE THE TIME FOR HOLDING THE AFORESAID MEETING.
- (b) The Register of Members and the share transfer books of the company will remain closed from 12th August 2008 to 22nd August 2008, both days inclusive.
- (c) An explanatory statement pursuant to Section 173 of the Companies Act, 1956 relating to Special Business is annexed hereto.
- (d) M/s. Intime Spectrum Registry Limited is the Registrar and Share Transfer Agent of the company. Shareholders are requested to make all correspondence including change of address to them at the following address.
M/s. Intime Spectrum Registry Limited
Unit: Span Diagnostics Limited
C-13, Pannalal Silk Mills Compound, L.B.S. Marg, Bhahdup (West), MUMBAI 400 078
Phone # 022-25963838, Fax # 022-25946969
Email: isrl@intimespectrum.com
- (e) Dividend as recommended by the Directors for the year ended 31st March 2008, if approved will be payable to those shareholders whose names appears in the Register of Members as at the close of business on 22nd August 2008 and the dividend warrants will be posted to them on or after the date of AGM.
- (f) Members are advised to avail of the facility for receipt of future dividends through Electronic Clearing Services (ECS). The ECS facility is available at the specified locations. Members holding shares in dematerialized mode are requested to contact their respective Depository Participants (DPs) for availing ECS facility. Members holding shares in physical form and desirous of availing ECS facility are requested to write to the company's Registrar & Share Transfer Agent for details.
- (g) Members who are holding shares in identical order of names in more than one account are requested to intimate to M/s Intime Spectrum Registry Limited at the address stated above with the ledger folio of such accounts together with the share certificates to enable them to consolidate all the holdings into one account. The share certificates will be returned to the members in due course after making the necessary endorsement.
- (h) Members are requested to bring their copy of the Annual Report to the Annual General Meeting. As a measure of economy, no extra copies of the Annual Report will be supplied at the meeting.
- (i) Members seeking further information on the Accounts or any other matter contained in the notice are requested to write to the company at least 7 days before the meeting so that relevant information can be kept ready at the meeting.



EXPLANATORY STATEMENT PURSUANT TO PROVISIONS OF SECTION 173 OF THE COMPANIES ACT 1956 AND INFORMATION PURSUANT TO CLAUSE 49 OF THE LISTING AGREEMENT

Resolution at Item No. 3, 4 & 5

Smt. Lataben P. Desai, aged 66, is an Arts Graduate. She was the Chairperson of the Board of Directors of the Company till 2nd May 2008 providing strategic direction to company's operations. Earlier, she also held the office of the Managing Director looking after day-to-day operations including product design solutions and administration. She does not hold directorship in other companies. She is the Chairperson of the Investors Grievances Committee of the Board. She holds 2,73,530 (8.68%) shares of the company as the first joint-holder and 4,87,790 (15.48%) shares as the second joint-holder in the company.

Mr. Sanjay Mehta, aged 57, is a Commerce Graduate. He is a Graduate member of the Institute of Cost and Works Accountants of India and a practicing Chartered Accountant at Mumbai having post-qualification experience of 33 years in the area of auditing, corporate advisory services in the field of domestic & international taxation, project finance, working capital appraisals, company-law compliances, company-secretarial matters, FEMA regulations, indirect taxes, management accounting, MIS etc. He is associated with the company since its inception and was looking after the Finance, taxation and company law matters earlier. He is also a director of Span Biotronics Pvt. Ltd., Span Finstock Pvt. Ltd. and Quest Bio-chemicals Pvt. Ltd. He is a member of Audit Committee, Investors Grievances Committee and Remuneration Committee of the Board. He holds 47,542 (1.51%) shares as the first joint-holder and 40,200 (1.28%) shares as the second joint-holder in the company.

Mr. Sarvajna Kazi, aged 44, is an Electrical Engineer and has done his Masters in Computer Science. He has also done his MBA from Stanford University, USA. He has wide experience in the field of management consultancy. He holds 5,000 (0.16%) shares of the company.

The Board recommends re-appointment of Smt. Lataben P. Desai, Mr. Sanjay Mehta and Mr. Sarvajna Kazi as directors of the company.

Smt. Lataben P. Desai, Mr. Sanjay Mehta and Mr. Sarvajna Kazi are deemed to be interested in the resolution. Dr. Pradip K. Desai being husband of Smt. Lataben P. Desai and father-in-law of Mr. Sarvajna Kazi, Mr. Veeral P. Desai being son of Smt. Lataben P. Desai and Mr. Sarvajna Kazi being son-in-law of Smt. Lataben P. Desai, are deemed to be interested in the resolutions.

Resolution at Item No. 7

The Board of Directors of the company at its meeting held on 28th June 2008 has appointed Mr. Kamlesh Patel as an Additional Director.

Mr. Kamlesh Patel, aged 51, is a Science Graduate. He has done his Masters in Law from South Gujarat University and is a practicing advocate at Surat since 1979. He is the Chairman of Surat Mercantile Co-operative Bank since 2002 and was a Managing Director of the bank during 1996-2004. He is a founder member of Surat Raktadan Kendra and Research Centre and a member of Managing Committee, Surat General Hospital. He is also a lecturer in Law, V.T. Choksi Sarvajnik Law College, Surat since 1987. He does not hold any shares in the company and is not a member of any committees of the Board.

The company has received a notice in writing from a member proposing the candidature of Mr. Kamlesh Patel for the office of director under the provisions of Section 257 of the Companies Act, 1956.

The Board recommends appointment of Mr. Kamlesh Patel as a Director of the Company.

None of the Directors of the company except Mr. Kamlesh Patel is anyway concerned or interested in the said resolution.

By Order of the Board

Jagdish Mehta
VP(Finance) & Company Secretary



DIRECTORS' REPORT

To,
The Shareholders,

Your Directors have pleasure in presenting the 28th Annual Report of the company together with the Audited Accounts for the year ended on 31st March 2008.

FINANCIAL RESULTS

The financial performance of the company for the financial year ended 31st March 2008 along with figures of previous financial year is summarized below:

	Rs. In lacs	
	2007-08	2006-07
Sales and other Income	6,489.78	5,554.09
Profit before Depreciation	647.62	458.68
Depreciation	144.66	110.80
Profit before tax	502.96	347.88
Provision of tax - Current	176.70	111.00
- Deferred Tax	16.28	11.12
- Fringe Benefit Tax	10.32	9.20
Prior period adjustments including provision for tax	3.29	8.20
Profit for the year	296.37	208.36
Balance brought forward	138.67	193.48
Amount available for appropriation	435.04	401.84
APPROPRIATIONS		
Proposed Dividend	63.00	54.00
Dividend Distribution tax	10.71	9.18
Transfer to General Reserve	22.50	200.00
Balance carried forward	338.83	138.66
	435.04	401.84

DIVIDEND

Your directors have recommended Rs. 2 per share (previous year Rs.1.80 per share) as dividend for the financial year ended 31st March 2008 aggregating to Rs.73.71 lacs including the dividend distribution tax.

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Industry structures and development

The in-vitro Diagnostic industry is going under major restructuring due to following factors:

- Increasing number of multinational companies are putting their investment in growing Indian market. A few of them have acquired Indian companies and are consolidating their presence. On the other side, the companies who are already established have undertaken major expansion in terms of their sales and marketing infrastructure. This year, the activity of merger and acquisition at global level has been more significant for MNCs who are present in India.
- During the year, the consolidation at customer level in terms of corporatization has gathered tremendous momentum. The corporate laboratories have started taking over the laboratories not only in Tier I but also in Tier II cities due to increased competition and also availability of finance options in the changing economy.
- The technician laboratories came under Govt. scanner and the legal fight is going on. The outcome of this case will have major impact on in-vitro diagnostic business and will change the business dynamics of diagnostic industry.

Opportunities and threat

Always in the growing market, there are opportunities available for growth with the correct strategy in marketing and manufacturing. Span is having a distinct advantage of possessing knowledge of many basic technologies for manufacturing in-vitro diagnostic products. Because of that there is a difference in set of opportunities and also threats in the time to come.

- Span can be more competitive in pricing and thus in a better position for participating in various Government programs.
- There is an increase in opportunity in forming business association with foreign companies having high-end technology and looking for a company who has manufacturing infrastructure, can assimilate their technology and produce the goods at competitive price.
- Overall increasing awareness about timely diagnosis and its advantages to the common man leads to market expansion.
- Tremendous export potential of the product in similar economies around the world.

Outlook

The high inflation and volatile economic condition will also impact the operational expenditure and will increase the pressure on the margin. Travelling expenditure, salary and wages are expected to increase substantially with the increase in the international crude oil price and double-digit inflation in India. The Government funding in various programs also will be affected as primary healthcare always gets a priority over the other healthcare programs. The company will have a challenge to make up for discontinued sale of various traded products aggregating to Rs.650 lacs in 2007-08. However, due to robust demand for the indigenously manufactured products, the company is hopeful of continuing its growth momentum and achieving its goals in line with its short term and long term goals.

Annual Report 2007-08

Risks and concerns

- Margin could come under pressure due to higher inflation, volatile economic conditions and higher overheads.
- Dependency on government programs.
- Highly competitive market conditions due to resourceful international companies and price cutting by domestic players.

Financial & Operating Performance 2007-08

Sales & Other income for the year increased to Rs.6489.78 lacs in 2007-08 showing a growth of 16.85% over previous year. During the year, the company executed tenders aggregating to Rs.13 crores under Government programs to combat AIDS and Malaria.

During the year, an old litigation in respect of excise duties got settled in favour of the company boosting Other Income by Rs.118.70 lacs. Exchange rate gain (net) of Rs.45.07 lacs (previous year Rs.7.85 lacs) also contributed to Other Income.

Manufacturing and other expenses increased in tandem with the increase in Sales. Wage-bill increase contributed 15.66%.

During the year, the company renovated its production and administrative facilities. The company also acquired technology from France for production of Monoclonal Antibodies. The benefits from the investment are expected to flow in the current year. The borrowing to finance the expansion project and increased working capital requirement resulted into higher interest cost for the year.

Profit before tax increased to Rs.502.96 lacs registering an increase of 45.49% contributing higher tax provision of Rs.176.70 lacs against Rs.111.00 lacs in the previous year.

Implementation of SAP ERP

Recognizing the need for better information flow for improved management decision-making, the company implemented ECC 6.0 version of SAP ERP consisting of Material Management, Production Planning, Quality Management, Sales and Distribution, Customer Support, Finance and Controlling.

Along with plant and corporate office, the company has integrated all the four branches namely, Bangalore, Gaziabad, Kolkata and Mumbai for on-line and seamless information flow throughout the company. This is expected to strengthen internal control and rationalize the inventory level further.

Internal Control system and their adequacy

During the year, the company appointed a reputed firm of Chartered Accountant to carry out the internal audit with focus on internal control and business processes. In addition, an in-house internal audit department focused on routine transactions and physical verification of inventory. Considering the size and level of activity of the company and implementation of SAP ERP, the present internal control system is adequate.

Human resources and industrial relations

The company has 598 employees comprising of trained technical and managerial personnel. The focus of the company is to enrich its employees by promoting learning and enhancing their knowledge by product training and arranging relevant training programs.

The Company continues to have cordial and harmonious relations with its employees and the union.

There are no employees drawing remuneration in excess of limits specified in section 217(A) of the Companies Act, 1956 read with Companies (Particulars of Employees) Rules, 1975.

SUBSIDIARIES AND JOINT VENTURES**Span Biotronics Private Limited (SBPL)**

With an objective to focus on development and manufacturing of new products, helping the company in improvement of existing manufacturing & servicing processes and sourcing of proper technology / technology transfer partners, the company incorporated SBPL with an aggregate investment of Rs.10 lacs in the form of equity shares and Rs.5 lacs in the form of preference shares. In addition, the company advanced Rs.26 lacs by way of short-term loan to SBPL.

SBPL has elaborate plans to launch a few products in the near future.

SBPL started its operations in February 2008 and has closed its books of accounts as at 29th March 2008 with a loss of Rs.23.80 lacs.

Span Diagnostics S.A.R.L. (France) (SARL)

To have an access to technology for production of Monoclonal Antibodies and to carry out research and development activities, the company has made a strategic investment by incorporating a joint-venture company with a stake of 49%.

Under the technology transfer agreement with SARL, the company has acquired the machineries and has got three employees trained to fully absorb the technology. The commercial production and sales of the product is expected to start from third quarter of 2008.

SARL has identified a few R&D projects targeting the commercial production in near future.

Span Diagnostics F.Z.C., Sharjah (FZC)

To tap the market of Middle East and African countries, to reduce the logistic cost and to provide better services in these regions, the company has incorporated FZC as a joint venture with a stake of 40%. FZC will be used as a marketing, distribution and logistic hub for products of the company.



The warehouse together with electricity and water connection could be allotted to FZC in May 08 only as against estimate of November 2007. FZC will commence its operations soon and its impact will be available in the next financial year.

Span Nihon Kohden Diagnostics Private Limited (SNKD)

The company was manufacturing some reagents under license from Nihon Kohden Corporation of Japan (NKC) for the instruments manufactured by NKC and sold by the company.

In April 2008, the company entered into a joint venture agreement with NKC for manufacture of reagents with the latest technology with company's stake at 45%. Accordingly, the company has incorporated SNKD initially as a 100% subsidiary company with investment from NKC to happen on receipt of regulatory approvals. SNKD is expected to commence commercial production in September 2008. On commencement of commercial production, the company will stop manufacturing these reagents. Under the JV agreement, the company will have an exclusive right to market the products in India.

CORPORATE GOVERNANCE

A report on Corporate Governance as stipulated under clause 49 of the Listing Agreement forms part of the Annual Report. The certificate from the Auditors of the company M/s Y.B. Desai & Associates confirming compliance with the conditions of Corporate Governance is attached to this Report.

DIRECTORS' RESPONSIBILITY STATEMENT

Your Directors confirm:

- (i) that in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- (ii) that the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year ended 31st March 2008 and of the profit of the Company for that year;
- (iii) that the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 1956 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (v) that the Directors have prepared the accounts on a going concern basis.

FIXED DEPOSITS

At the close of the year, there were no fixed deposits due for payment which remained either unclaimed or unpaid. There were no claims as against the deposits outstanding as at the close of the year and the Company had complied with all the requirements of the Companies (Acceptance of Deposits) Rules, 1975.

CONSERVATION OF ENERGY

The particulars are as per Annexure 'A'.

TECHNOLOGY ABSORPTION, RESEARCH & DEVELOPMENT AND FOREIGN EXCHANGE EARNING & OUTGO

The particulars are as per Annexure 'B'.

DIRECTORS

Mrs. Lataben Desai, Mr. Sarvajna Kazi and Mr. Sanjay Mehta, Directors of the company retire by rotation at the ensuing Annual General Meeting and being eligible offer themselves for reappointment. The Board Places on record its appreciation for contribution made by Mr. Praful R Gandhi throughout his tenure as a director of the company. Mr. Kamlesh Patel was appointed as an Additional Director of the Company. He will hold the office of director upto the date of ensuing Annual General Meeting.

CAUTIONARY STATEMENT

Statements in this Report, particularly those which relate to Management Discussion and Analysis and the Corporate Governance Report, describing the Company's objectives, projections, estimates and expectations may constitute "forward looking statement" within the meaning of applicable laws and regulations. Actual results may differ materially from those either expressed or implied in the statement depending on the circumstances.

AUDITORS AND AUDITORS' REPORT

M/s Y. B. Desai & Associates, Chartered Accountants, the auditors of the company are eligible for their re-appointment. The directors recommend their re-appointment for the current year.

The Notes on accounts, referred to in the Auditor's Report, are self explanatory and therefore do not call for any further comments.

ACKNOWLEDGEMENT

Your Directors are happy to place on record their appreciation of the whole-hearted co-operation and hard work of all members of SPAN family. The Directors would like to place on record a deep sense of gratitude to the Kotak Mahindra Bank Limited, State Bank of India, ICICI Bank, Standard Chartered Bank, HDFC Bank and Government Authorities for their co-operation and assistance rendered to the Company.

For and on behalf of the Board

Place: Surat
Dated: 28th June 2008

Dr. Ramnik Parekh
Chairman

Veeral P. Desai
Managing Director

ANNEXURE 'A'

PARTICULARS PERTAINING TO CONSERVATION OF ENERGY

	Particulars	2007-08	2006-07
A.	Power and fuel consumption		
1.	Electricity		
a)	Purchased		
	Unit (in '000 Kwh)	1929	1794
	Total amount (Rs. in lacs)	91.37	85.32
	Rate/unit (Rs.)	4.74	4.75
b)	Own generation		
(i)	Through diesel generator		
	Unit (in '000 Kwh)	32	49
	Unit per liter of diesel Oil	2.55	2.49
	Cost/Unit (in Rs.)	14.35	14.22
(ii)	Through steam turbine/generator	N.A.	N.A.
	Unit (in '000 Kwh)		
	Unit per liter of fuel		
	Cost/Unit (in Rs.)		
2.	Coal (Specify quality and where used)	N.A.	N.A.
	Quantity (tones)		
	Total cost		
	Average Rate		
3.	Light Diesel Oil		
	Quantity (K. Liter)	18,381	14,110
	Total Amount (Rs. In lacs)	7.27	5.33
	Average Rate (Rs./K. Liter)	39,567	37,748
4.	Other/Internal generation		
	Total Cost	Nil	Nil
	Rate / Unit	Nil	Nil
B.	Consumption per unit of production	Standards if any	
	Products	Considering the number of products being manufactured by the company and production activity not being energy sensitive, the Company is not in a position to give the information required as per this format for the current year as well as the previous year. Regular steps are being taken to improve the energy conservation.	
	Units		
	Electricity		
	Furnace Oil		
	Coal		
	Others		

ANNEXURE 'B'

Form of disclosure of particulars with respect to Absorption of Technology, Research & Development (R & D)

1. Specific areas in which R&D was carried out by the company:

The company has In-house R&D unit which is recognized by the Department of Scientific and Industrial Research. The said R&D Unit provides significant support to the business through continuous innovation of products, processes, packaging modes and services. Full fledged R & D work is carried out for development of diagnostics products, reagent chemicals, packaging and analytical process. Currently, the company is focusing on

- Modification of existing HIV Kit
- Manufacture of recombinant antigens for Treponema
- Manufacture of Lateral flow test for Tuberculosis etc.

2. Benefits derived as a result of the above R & D:

- Productivity and quality improvement.
- Product design and operating efficiencies
- Cost reduction.
- Import substitution of critical raw materials and Diagnostic reagents

3. Future plans:

The R & D activity will continue to emphasis main area set out above and especially on the development of new technologies, new products and processes.



4. Expenditure on R & D

Sr. No.	Description	Year ended 31 March 08 (Rs.)	Year ended 31 March 07 (Rs.)
a.	Capital	9,24,766	977,984
b.	Recurring	71,49,080	3,350,727
c.	Total	80,73,852	4,438,711
d.	Total R & D expenditure as percentage of total Turnover	1.29%	0.83%

5. Technology absorption, adaptation and innovation

Efforts in brief, made towards technology absorption, adaptation and innovation:

The processes for new formulations were adopted by modifying them to suit local equipments and raw materials specification. Innovations were made to improve the yield.

Benefits derived as a result of the above efforts e.g. product improvement, cost reduction, product development, import substitution etc.
Cost reduction was achieved due to replacement of imported raw materials with indigenous raw materials developed by R&D. The status of absorption of technology imported for last five years are given below:

Sr. No.	Technology imported	Year of Import	Has the technology been fully absorbed ?	If not fully absorbed, areas where this has not taken place, reasons therefore and future plans of action.
a.	Manufacture of diagnostics kit for detection of Cholera	2004	Yes	Not applicable
b.	Manufacture of diagnostics kit for detection of 'Yersinia pestis'	2006	Yes	Not applicable
c.	Manufacture of anti-sera, monoclonal antibodies and related products for the purpose of blood grouping etc.	2006	Yes	Not applicable
d.	Manufacture of fourth generation ELISA for HIV	2006	Yes	Not applicable
e.	Manufacture of fourth generation ELISA for Syphilis	2007	Under process	Not applicable

In addition, the company has also acquired technologies within India for manufacture of recombinant antigens for Leishmania, recombinant antigen of Malaria, antibodies against them and recombinant antigens for microfilaria.

5. FOREIGN EXCHANGE EARNING AND OUTGO

	Rs. in Lacs
1. Total Foreign Exchange Earned	447.63 (410.22)
2. Total Foreign Exchange Outgo	1887.81 (2195.55)

For and on behalf of the Board

Place: Surat
Dated: 28th June 2008

Dr. Ramnik Parekh
Chairman

Veeral P. Desai
Managing Director